ArticleNeoplasia (New York, N.Y.)2026
Integrated collagen architecture and composition improve risk stratification in triple-negative breast cancer.
Article in Neoplasia (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
9 authors.
Funding
Abstract
Triple-negative breast cancer (TNBC) exhibits substantial clinical heterogeneity, with some patients experiencing early recurrence and poor survival despite similar clinicopathologic features. Here, we investigated whether quantitative assessment of intratumoral collagen architecture and composition could improve risk stratification in TNBC. We analyzed a retrospective cohort of 79 TNBC tumors assembled into tissue microarrays using a multimodal computational pathology framework integrating Masson Trichrome staining with COL1 and COL3 immunohistochemistry. Collagen architecture was quantified using fiber-based image analysis and unsupervised clustering, while collagen composition was assessed using a normalized COL3:COL1 ratio. Unsupervised analysis identified four distinct collagen architectural states, which were consolidated into low-risk and high-risk groups based on recurrence patterns. High-risk collagen architecture was associated with shorter recurrence-free interval (log-rank p = 0.025; restricted mean survival time difference=10.1 months). Independently, a higher COL3:COL1 ratio was associated with improved overall survival (log-rank p = 0.042; restricted mean survival time difference=9.4 months). Integration of collagen architecture and composition further refined risk stratification, with patients demonstrating high-risk architecture and low COL3:COL1 ratios exhibiting the poorest outcomes. Notably, collagen-defined phenotypes identified patients with divergent outcomes not readily apparent from tumor stage alone. Together, these findings demonstrate that quantitative assessment of intratumoral collagen architecture and composition provides clinically meaningful prognostic information in TNBC and supports extracellular matrix phenotyping as a practical computational pathology approach for refining risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.